Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 30Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Breast Neoplasms 3Prostate Carcinoma Metastatic to the Bone 2Neoplasms 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Pain 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lung Neoplasms 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × radium Ra 223 dichloride × Clear all
NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
40 enrolled 18 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Bayer

Phase 2 Completed
122 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01798108 2017-05-19

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Bayer

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Bayer

Phase 2 Completed
64 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00748046 2014-06-25

Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Bayer

Phase 1 Completed
10 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡